학술논문
Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study
Document Type
article
Author
Matteo Bauckneht; Sara Elena Rebuzzi; Marta Ponzano; Roberto Borea; Alessio Signori; Viviana Frantellizzi; Elisa Lodi Rizzini; Manlio Mascia; Valentina Lavelli; Alberto Miceli; Maria Silvia De Feo; Antonio Rosario Pisani; Susanna Nuvoli; Vincenzo Tripoli; Alessio Giuseppe Morganti; Paolo Mammucci; Salvatore Caponnetto; Guglielmo Mantica; Angelo Domenico Di Nicola; Carlo Villano; Luca Cindolo; Silvia Morbelli; Gianmario Sambuceti; Stefano Fanti; Renato Patrizio Costa; Angela Spanu; Giuseppe Rubini; Fabio Monari; Giuseppe De Vincentis; Giuseppe Fornarini
Source
Cancers, Vol 14, Iss 7, p 1744 (2022)
Subject
Language
English
ISSN
2072-6694
Abstract
The multicentric retrospective BIO-Ra study combined inflammatory indices from peripheral blood and clinical factors in a composite prognostic score for metastatic castration-resistant prostate cancer patients receiving Radium-223 (Ra-223). In the present study, we evaluated (i) the prognostic power of the BIO-Ra score in the framework of the restricted use of Ra-223 promoted by the European Medicines Agency in 2018; (ii) the treatment completion prediction of the BIO-Ra score. Four hundred ninety-four patients from the BIO-Ra cohort were divided into three risk classes according to the BIO-Ra score to predict the treatment completion rate (p < 0.001 among all the three groups). Patients receiving Ra-223 after restriction (89/494) were at later stages of the disease compared with the pre-restriction cohort (405/494), as a higher percentage of BIO-Ra high-risk classes (46.1% vs. 34.6%) and lower median Overall survival (12.4 vs. 23.7 months, p < 0.001) was observed. Despite this clinically relevant difference, BIO-Ra classes still predicted divergent treatment completion rates in the post-restriction subgroup (72%, 52.2%, and 46.3% of patients belonging to low-, intermediate-, and high-risk classes, respectively). Although the restricted use has increased patients at higher risk with unfavourable outcome after Ra-223 treatment, the BIO-Ra score maintains its prognostic value.